|
|
Article: Pain Therapeutics Completes Patient Enrollment for Phase III Study with Oxytrex(TM).
- Article from:
- PR Newswire
- Article date:
- September 8, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Clinical Results Expected Q1 2005
Pain Therapeutics, Inc. , a biopharmaceutical company, today announced it successfully completed enrollment in a Phase III study of over 700 patients with severe low-back pain. This study compares oxycodone against Oxytrex, a new drug being developed to provide superior and prolonged pain relief.
"We're delighted patient enrollment for this pivotal Phase III study is on-time and on-budget," said Remi Barbier, Pain Therapeutics' president and chief executive officer. "Patients with chronic low-back pain may not experience complete pain relief over time with oxycodone. We believe Oxytrex offers hope for these patients and ...